Compare SIGA & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIGA | ELMD |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 204.1M |
| IPO Year | 2016 | 2010 |
| Metric | SIGA | ELMD |
|---|---|---|
| Price | $2.41 | $23.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | ★ 535.8K | 38.8K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | ★ 22.64% | N/A |
| EPS Growth | N/A | ★ 52.94 |
| EPS | 0.09 | ★ 0.32 |
| Revenue | N/A | ★ $54,716,000.00 |
| Revenue This Year | N/A | $11.55 |
| Revenue Next Year | $205.62 | $10.94 |
| P/E Ratio | ★ $29.56 | $72.69 |
| Revenue Growth | N/A | ★ 13.83 |
| 52 Week Low | $2.51 | $22.67 |
| 52 Week High | $7.11 | $47.40 |
| Indicator | SIGA | ELMD |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 27.51 |
| Support Level | N/A | $23.03 |
| Resistance Level | $3.43 | $24.99 |
| Average True Range (ATR) | 0.24 | 1.24 |
| MACD | -0.06 | -0.29 |
| Stochastic Oscillator | 1.21 | 8.17 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Electromed Inc is a United States-based company that develops, manufactures and markets airway clearance products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The company markets its products in the U.S. to the homecare and hospital markets. Its product includes the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The company operates in a single segment: developing, manufacturing, and marketing medical equipment. The company generates revenue from Homecare, Hospital, Homecare Distributor, and Other.